Project Details
Description
A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) vs. Prednisone in Metastatic Castrationresistant Prostate Cancer Patients who have Received Prior Docetaxel and Prior Abiraterone or MDV3100
| Status | Finished |
|---|---|
| Effective start/end date | 7/1/12 → 7/30/16 |
Funding
- EXELIXIS, INC
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.